STOCK TITAN

[Form 4] PFIZER INC Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Pfizer Inc. (PFE) Chairman & CEO Albert Bourla reported acquiring 83 phantom stock units on 10/14/2025 at a derivative security price of $24.52. Following this transaction, he beneficially owns 731,058 derivative securities. Each unit represents one share of common stock and was acquired under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, with settlement in cash after separation from service.

Pfizer Inc. (PFE) Il presidente e amministratore delegato Albert Bourla ha riferito di aver acquistato 83 unità di azioni fantasma il 14/10/2025 a un prezzo di strumenti derivati di 24,52 dollari. A seguito di questa operazione, detiene in modo vantaggioso 731.058 strumenti derivati. Ogni unità rappresenta una quota di azioni ordinarie ed è stata acquisita ai sensi del Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, con regolamento in contanti dopo la separazione dal servizio.

Pfizer Inc. (PFE) El presidente y director ejecutivo Albert Bourla informó haber adquirido 83 unidades de acciones fantasma el 14/10/2025 a un precio de valor de seguridad derivada de 24,52 dólares. Tras esta operación, posee beneficiariamente 731,058 valores derivados. Cada unidad representa una acción común y fue adquirida bajo el Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, con liquidación en efectivo tras la separación del servicio.

Pfizer Inc. (PFE) 의 회장 겸 CEO인 Albert Bourla는 83개의 팬텀 주식 유닛2025-10-14에 파생증권 가격 24.52달러로 취득했다고 보고했습니다. 이 거래에 따라 그는 실질적으로 731,058개의 파생증권을 보유합니다. 각 유닛은 보통주의 한 주를 대표하며, Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan에 따라 취득되었으며, 서비스 종료 시 현금으로 정산됩니다.

Pfizer Inc. (PFE) Le président-directeur général Albert Bourla a annoncé avoir acquis 83 unités d'actions fantômes le 14/10/2025 à un prix de valeur dérivée de 24,52 dollars. Suite à cette transaction, il détient bénéficiellement 731 058 valeurs dérivées. Chaque unité représente une action ordinaire et a été acquise dans le cadre du Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, avec règlement en espèces après la cessation de service.

Pfizer Inc. (PFE) Vorsitzender und CEO Albert Bourla meldete den Erwerb von 83 Phantomaktien-Einheiten am 14.10.2025 zu einem Derivatewert von 24,52 USD. Nach dieser Transaktion besitzt er vorteilhaft 731.058 Derivatewerte. Jede Einheit repräsentiert eine einzelne Stammaktie und wurde im Rahmen des Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan erworben, mit Barauszahlung nach Beendigung des Dienstverhältnisses.

Pfizer Inc. (PFE) أعلن رئيس مجلس الإدارة والمدير التنفيذي ألبرت بورلا عن اكتسابه 83 وحدة أسهم وهمية في 14/10/2025 بسعر أداة مشتقة قدره 24.52 دولارًا. عقب هذه المعاملة، يمتلك بشكل مستفيد 731,058 من الأوراق المالية المشتقة. كل وحدة تمثل سهماً عادياً واحداً وتم اكتسابها بموجب Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan، مع التسوية نقداً بعد انتهاء الخدمة.

Pfizer Inc. (PFE) 董事长兼首席执行官 Albert Bourla 报告在 2025-10-14 以衍生证券价格 24.52 美元购得 83 股幻股单位。此交易后,他实质持有 731,058 份衍生证券。每单位代表一股普通股,依据 Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan 计划取得,离职后以现金结算。

Positive
  • None.
Negative
  • None.

Pfizer Inc. (PFE) Il presidente e amministratore delegato Albert Bourla ha riferito di aver acquistato 83 unità di azioni fantasma il 14/10/2025 a un prezzo di strumenti derivati di 24,52 dollari. A seguito di questa operazione, detiene in modo vantaggioso 731.058 strumenti derivati. Ogni unità rappresenta una quota di azioni ordinarie ed è stata acquisita ai sensi del Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, con regolamento in contanti dopo la separazione dal servizio.

Pfizer Inc. (PFE) El presidente y director ejecutivo Albert Bourla informó haber adquirido 83 unidades de acciones fantasma el 14/10/2025 a un precio de valor de seguridad derivada de 24,52 dólares. Tras esta operación, posee beneficiariamente 731,058 valores derivados. Cada unidad representa una acción común y fue adquirida bajo el Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, con liquidación en efectivo tras la separación del servicio.

Pfizer Inc. (PFE) 의 회장 겸 CEO인 Albert Bourla는 83개의 팬텀 주식 유닛2025-10-14에 파생증권 가격 24.52달러로 취득했다고 보고했습니다. 이 거래에 따라 그는 실질적으로 731,058개의 파생증권을 보유합니다. 각 유닛은 보통주의 한 주를 대표하며, Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan에 따라 취득되었으며, 서비스 종료 시 현금으로 정산됩니다.

Pfizer Inc. (PFE) Le président-directeur général Albert Bourla a annoncé avoir acquis 83 unités d'actions fantômes le 14/10/2025 à un prix de valeur dérivée de 24,52 dollars. Suite à cette transaction, il détient bénéficiellement 731 058 valeurs dérivées. Chaque unité représente une action ordinaire et a été acquise dans le cadre du Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, avec règlement en espèces après la cessation de service.

Pfizer Inc. (PFE) Vorsitzender und CEO Albert Bourla meldete den Erwerb von 83 Phantomaktien-Einheiten am 14.10.2025 zu einem Derivatewert von 24,52 USD. Nach dieser Transaktion besitzt er vorteilhaft 731.058 Derivatewerte. Jede Einheit repräsentiert eine einzelne Stammaktie und wurde im Rahmen des Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan erworben, mit Barauszahlung nach Beendigung des Dienstverhältnisses.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BOURLA ALBERT

(Last) (First) (Middle)
66 HUDSON BOULEVARD EAST
ATTN: CORPORATE SECRETARY

(Street)
NEW YORK NY 10001-2192

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chairman & CEO
3. Date of Earliest Transaction (Month/Day/Year)
10/14/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Phantom Stock Units SSP (1) 10/14/2025 A 83 (2) (2) Common Stock 83 $24.52 731,058 D
Explanation of Responses:
1. Each unit represents one phantom share of common stock.
2. These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
/s/ Shanice A. Reid, by power of atty., for Albert Bourla 10/16/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Pfizer

NYSE:PFE

PFE Rankings

PFE Latest News

PFE Latest SEC Filings

PFE Stock Data

138.67B
5.68B
0.07%
67.08%
1.82%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
NEW YORK